AVVAA World Health Care Products, Inc. (AVVH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AVVAA World Health Care Products, Inc. (AVVH) with AI Score 48/100 (Weak). AVVAA World Health Care Products, Inc. is a biotechnology company focused on manufacturing and marketing skincare products. It operates as a subsidiary of Gold Quest Capital, Inc. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 16, 2026AVVAA World Health Care Products, Inc. (AVVH) Financial Services Profile
AVVAA World Health Care Products, Inc., a subsidiary of Gold Quest Capital, operates within the financial services sector as a shell company focused on biotechnology. It develops, manufactures, and markets the Neuroskin line and distributes patented European skincare and animal care products, primarily through mass marketing channels.
Investment Thesis
AVVAA World Health Care Products, Inc. presents a speculative investment opportunity given its status as a shell company operating in the biotechnology sector. Key value drivers include the potential for revenue generation from its Neuroskin line and licensed European skincare products. However, the company's negative profit margin of -17.7% and a high P/E ratio of -230.77 indicate financial challenges. Growth catalysts depend on successful marketing and distribution strategies, particularly within mass market channels. Potential risks include the company's reliance on its parent company, Gold Quest Capital, Inc., its limited number of employees (5), and the competitive nature of the skincare market. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a very small company size and potential liquidity concerns.
- Negative P/E ratio of -230.77 reflects the company's current unprofitability.
- Profit margin of -17.7% suggests operational inefficiencies or high costs relative to revenue.
- Gross margin of 25.0% indicates the company's ability to generate profit from its products before operating expenses.
- Beta of 0.99 suggests the stock's price is nearly as volatile as the market.
Competitors & Peers
Strengths
- Proprietary Neuroskin product line.
- Distribution rights for patented European skincare products.
- Focus on natural and therapeutic ingredients.
- Established presence in mass marketing channels.
Weaknesses
- Small company size with limited resources.
- Negative profit margin and high P/E ratio.
- Reliance on parent company, Gold Quest Capital, Inc.
- Limited number of employees.
Catalysts
- Upcoming: Potential new product launches in the Neuroskin line.
- Upcoming: Strategic partnerships with major retailers to expand distribution.
- Ongoing: Increased marketing and promotion of existing product lines.
- Ongoing: Expansion of online sales channels and e-commerce initiatives.
Risks
- Potential: Limited financial resources and negative profit margin.
- Potential: Intense competition in the skincare and animal care markets.
- Potential: Reliance on parent company, Gold Quest Capital, Inc.
- Ongoing: Low liquidity and trading volume of the stock.
- Ongoing: Limited financial disclosure and regulatory oversight.
Growth Opportunities
- Expansion of the Neuroskin product line: The market for skincare products addressing specific skin abnormalities is growing, driven by increasing consumer awareness and demand for effective solutions. AVVAA can capitalize on this trend by expanding its Neuroskin product line and targeting specific skin conditions. Successful product development and marketing could significantly increase revenue within the next 2-3 years.
- Increased distribution of European skincare products: AVVAA's distribution rights for patented European skincare products provide a unique opportunity to access scientifically developed treatments for skin diseases like eczema, psoriasis, and acne. Expanding distribution channels and marketing efforts can drive sales growth in this segment. This expansion can be achieved within the next year through strategic partnerships with retailers and online platforms.
- Development of new animal care products: The market for natural animal care products is expanding as pet owners increasingly seek high-quality grooming treatments for their pets. AVVAA can leverage its expertise in natural formulations to develop new and innovative animal care products, targeting specific needs and preferences. New product launches could generate revenue growth within the next 1-2 years.
- Strategic partnerships with retailers: Collaborating with major retailers can significantly expand AVVAA's reach and increase product visibility. Establishing partnerships with food and drug stores, as well as online retailers, can drive sales growth and market share. These partnerships can be established within the next 6-12 months through targeted outreach and negotiation.
- Online marketing and e-commerce initiatives: Investing in online marketing and e-commerce platforms can enhance AVVAA's brand awareness and drive direct sales to consumers. Developing a user-friendly website and engaging in social media marketing can attract new customers and build brand loyalty. These initiatives can be implemented within the next 3-6 months, leading to increased online sales and brand recognition.
Opportunities
- Expansion of the Neuroskin product line.
- Increased distribution of European skincare products.
- Development of new animal care products.
- Strategic partnerships with retailers.
Threats
- Intense competition in the skincare and animal care markets.
- Changing consumer preferences and trends.
- Regulatory requirements and compliance.
- Economic downturns affecting consumer spending.
Competitive Advantages
- Proprietary Neuroskin product line with formulations for specific skin conditions.
- Distribution rights for patented European skincare products.
- Focus on natural and therapeutic ingredients.
- Established presence in mass marketing channels.
About AVVH
Incorporated in 1998 and based in Richmond, Virginia, AVVAA World Health Care Products, Inc. is a biotechnology company specializing in natural and therapeutic skin care products. The company's primary focus is the manufacturing and marketing of its over-the-counter Neuroskin line, designed for treating skin abnormalities and enhancing skin clarity. These products are distributed through mass marketing channels, including food and drug stores. AVVAA also holds distribution rights for patented European skin care products scientifically formulated to address symptoms of skin diseases such as eczema, psoriasis, and acne. Additionally, the company offers a line of natural animal care products, including grooming treatments for dogs, cats, horses, and other pets. As of June 23, 2021, AVVAA World Health Care Products, Inc. operates as a subsidiary of Gold Quest Capital, Inc. The company's business model involves leveraging its proprietary and licensed product lines to cater to both human and animal skincare needs, with a focus on over-the-counter solutions and mass-market distribution.
What They Do
- Develops and manufactures the Neuroskin line of skincare products.
- Markets Neuroskin products for treating skin abnormalities.
- Distributes patented European skincare products for skin diseases.
- Offers natural animal care products for pets.
- Focuses on mass marketing through food and drug channels.
- Operates as a subsidiary of Gold Quest Capital, Inc.
Business Model
- Manufacturing and selling the Neuroskin line of over-the-counter skincare products.
- Distributing patented European skincare products through licensing agreements.
- Offering a range of natural animal care products for various pets.
- Generating revenue through mass marketing and distribution channels.
Industry Context
AVVAA World Health Care Products, Inc. operates within the competitive skincare and animal care products industry. The market is characterized by a mix of established players and emerging brands, with trends including increasing demand for natural and therapeutic products. AVVAA's positioning as a biotechnology company focused on over-the-counter solutions places it in competition with both mass-market brands and specialized skincare companies. The company's success depends on its ability to differentiate its products and effectively reach consumers through mass marketing channels.
Key Customers
- Individuals seeking over-the-counter solutions for skin abnormalities.
- Consumers looking for natural and therapeutic skincare products.
- Pet owners seeking grooming treatments for their animals.
- Retailers and distributors in the food and drug channels.
Financials
Chart & Info
AVVAA World Health Care Products, Inc. (AVVH) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVVH.
Price Targets
Wall Street price target analysis for AVVH.
MoonshotScore
What does this score mean?
The MoonshotScore rates AVVH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Jason Price
Managing
Jason Price serves as the managing person for AVVAA World Health Care Products, Inc., overseeing the operations of a small team of five employees. Information regarding his prior experience and educational background is not available. His role involves directing the company's efforts in manufacturing, marketing, and distributing skincare and animal care products.
Track Record: Due to the limited information available, Jason Price's track record and key achievements at AVVAA World Health Care Products, Inc. cannot be assessed. There is no available data regarding strategic decisions or company milestones under his leadership.
AVVH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AVVAA World Health Care Products, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and higher volatility compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in AVVH.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for price manipulation due to low trading volume.
- Higher volatility compared to exchange-listed stocks.
- OTC Other tier companies may not meet minimum financial standards.
- Verify the company's financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Review the company's legal and regulatory filings.
- Determine the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC Other tier companies.
- Subsidiary of Gold Quest Capital, Inc.
- Focus on natural and therapeutic skincare products.
- Distribution rights for patented European skincare products.
AVVAA World Health Care Products, Inc. Stock: Key Questions Answered
What does AVVAA World Health Care Products, Inc. do?
AVVAA World Health Care Products, Inc. is a biotechnology company that develops, manufactures, and markets natural and therapeutic skincare and animal care products. Its primary focus is on the Neuroskin line, designed to treat skin abnormalities and enhance skin clarity, distributed through mass marketing channels. Additionally, the company holds distribution rights for patented European skincare products and offers a line of natural animal care products. As a subsidiary of Gold Quest Capital, Inc., AVVAA leverages its proprietary and licensed product lines to cater to both human and animal skincare needs.
What do analysts say about AVVH stock?
AI analysis is currently pending for AVVH. Given its status as an OTC-listed shell company with a small market capitalization and negative profitability metrics, analyst coverage is likely limited. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in such companies. Key valuation metrics, such as the negative P/E ratio, reflect the company's current financial challenges. Growth considerations depend on successful product development, marketing strategies, and strategic partnerships.
What are the main risks for AVVH?
The main risks for AVVH include its limited financial resources, negative profit margin, and reliance on its parent company, Gold Quest Capital, Inc. As an OTC-listed company, AVVH faces risks related to low liquidity, limited financial disclosure, and potential price manipulation. Intense competition in the skincare and animal care markets, changing consumer preferences, and regulatory requirements also pose significant challenges. Investors should carefully assess these risks before considering an investment in AVVH.
What are the key factors to evaluate for AVVH?
AVVAA World Health Care Products, Inc. (AVVH) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary Neuroskin product line.. Primary risk to monitor: Potential: Limited financial resources and negative profit margin.. This is not financial advice.
How frequently does AVVH data refresh on this page?
AVVH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AVVH's recent stock price performance?
Recent price movement in AVVAA World Health Care Products, Inc. (AVVH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Neuroskin product line.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AVVH overvalued or undervalued right now?
Determining whether AVVAA World Health Care Products, Inc. (AVVH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AVVH?
Before investing in AVVAA World Health Care Products, Inc. (AVVH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market investments carry higher risk than exchange-listed stocks.